ParcelBio
Latest round
- Seed
Last raised
- Feb 2026
Total raised
- $13M
Investors
- 7
About ParcelBio
, ParcelBio provides RNA-based drugs. The company was co-founded by David Weinberg (CEO), and Chris Carlson. The company offers programmable technology that delivers mRNA to various cell types throughout the body. The firm Stabilized Targeted mRNA Platform (STAmP) offers a nanoparticle-free solution. It stabilizes mRNA and incorporates an interchangeable lock-and-key-like targeting mechanism, enabling fully customizable mRNA medicines tailored to specific therapeutic needs.
Who invested in ParcelBio
7 investors across 2 rounds
See all investors in ParcelBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ParcelBio
Who invested in ParcelBio?
ParcelBio has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ParcelBio raised?
ParcelBio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did ParcelBio last raise money?
ParcelBio's most recent round on record is a Seed, in Feb 2026.
What does ParcelBio do?
, ParcelBio provides RNA-based drugs.
Where is ParcelBio headquartered?
ParcelBio is headquartered in San Francisco, US.
Which VCs invest in companies like ParcelBio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ParcelBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like ParcelBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.